The atopic dermatitis therapeutics market is poised for steady growth, with revenues projected to rise from USD 15.43 billion in 2024 to USD 29.5 billion by 2033. This reflects a compound annual growth rate (CAGR) of 7.5%. Market expansion is driven by the rising prevalence of atopic dermatitis, growing demand for therapeutics, advancements in the understanding of its pathophysiology, increased pharmaceutical spending, and improved diagnostic capabilities. Ongoing research is focusing on identifying biomarkers for personalized treatment approaches. Although an ideal biomarker has not yet been established, serum eosinophil-derived neurotoxin (EDN) correlates with disease severity and can predict relapses in patients with severe, treatment-resistant atopic dermatitis. 

Atopic dermatitis a chronic, inflammatory skin disorder characterized by redness, irritation, and intense itching. It is one of the most prevalent dermatological conditions globally, affecting both children and adults, though its onset typically occurs during infancy. In 2023, approximately 15-20% of children and 1-3% of adults worldwide were affected by atopic dermatitis. While not contagious, the condition significantly impacts patients’ quality of life (QoL) due to its frequent flare-ups. Persistent itching, the hallmark symptom, often leads to scratching, which worsens skin damage, triggers secondary infections, and exacerbates the disease.

To Get more Insights,  Request A Free Sample 

Etiologic and Risk Factors

Genetic factors play a major role in atopic dermatitis, with a 50-80% likelihood of development if one or both parents are affected. Mutations in the filaggrin gene, which impair skin barrier function, are found in up to 30% of patients and may also predispose individuals to conditions like ichthyosis vulgaris and allergic rhinitis.

Environmental factors, including pollution, tobacco, smoke, and exposure to harsh chemicals, further weaken the skin barrier. Food hypersensitivities, particularly to eggs, milk, peanuts, soy, and wheat, exacerbate symptoms in 10-30% of cases. Additionally, inflammation contributes to itching, fuelling the destructive itch-scratch cycle.

A 2024 Oxford Academic report estimates that 2.6% of the global population (approximately 204 million people) are affected by atopic dermatitis, including 101 million adults and 103 million children.

Driver: Rising Global Prevalence of Atopic Dermatitis

Dermatological disorders are on the rise globally. According to the World Health Organization (WHO), skin conditions affect an estimated 1.8 billion people at any given time. Among these, atopic dermatitis is particularly prevalent. In 2022, approximately 223 million people were living with atopic dermatitis worldwide. The condition is especially common in high-income countries.
Atopic dermatitis is most seen in younger age groups, especially infants and toddlers. As of 2025, the global paediatric population is estimated to be around 2 billion children who age 0-14 years. This condition often begins between 3 and 6 months of age, with about 65% of children showing symptoms before they turn one, and 90% before the age of five. Since it appears so early in life, it has become a major concern for many parents. With growing awareness, rising number of young children are being diagnosed with atopic dermatitis parallelly producing driving the demand for safer and more effective treatment options. 

Challenge: High Cost of Advanced Atopic Dermatitis Therapies

One of the major barriers to the growth of the atopic dermatitis therapeutics market is the high cost of advanced treatments, particularly biologics and combination therapies. Atopic dermatitis is a chronic condition and often requires long-term, multifaceted treatment. This can impose a significant financial burden on patients.

According to a 2019 survey conducted by the National Eczema Association (NEA), which included responses from 1,118 individuals living with atopic dermatitis in the United States, 42% of patients reported spending more than $1,000 per year to manage their condition. The median out-of-pocket cost was $600 annually, and 8.5% of respondents indicated spending over $5,000 per year.

Moreover, the severity of the disease directly influences the overall cost burden. Annual all-cause direct healthcare costs ranged from $8,936 for patients with mild symptoms, to $11,755 for those with moderate symptoms, and up to $23,242 for patients with severe atopic dermatitis. These costs are not limited to medication and therapy but also include frequent physician consultations and emergency room visits, which are common among individuals with poorly controlled or severe atopic dermatitis.

Without reform in reimbursement policies and pricing strategies, market expansion may be limited despite rising disease burden and promising treatment advances.

Market Opportunity: Advancements in Biologics and Targeted Therapies for Atopic Dermatitis

The atopic dermatitis therapeutics market is witnessing a transformative shift driven by innovation in biologics and targeted therapies. As the understanding of atopic dermatitis’s complex immune pathophysiology deepens, emerging biologic treatments are providing highly targeted mechanisms of action that offer improved efficacy and disease control, especially for patients unresponsive to conventional therapies.

Biologics targeting specific immune pathways, such as IL-4, IL-13, IL-22, IL-31, TSLP, and OX40-OX40L have demonstrated substantial clinical benefits. A significant proportion of patients treated with these agents have achieved EASI-75 responses, a key benchmark in disease severity reduction. For example, clinical trials with nemolizumab, an IL-31 inhibitor, have shown a marked reduction in pruritus over 64 weeks in patients with moderate to severe AD who had limited success with topical treatments or antihistamines.

Further highlighting the market potential, ongoing research like Pfizer’s multi centre observational trial on abrocitinib is studying how it is effective in patients with moderate-to-severe atopic dermatitis who haven’t responded to one or two previous biologic treatments. These developments suggest a strong pipeline that could lead to more treatment options and support long term market growth.

With the increasing demand for personalized and effective treatments, the continued advancement of biologics and targeted therapies represents a key growth opportunity for stakeholders in the global atopic dermatitis therapeutic market.

Segmental Analysis

By Age: Children Lead the Atopic Dermatitis Therapeutic Market, Followed by Older Adults

The global atopic dermatitis therapeutic market is segmented by age into children (0-17 years), adults (18-74 years), and older adults (75-99 years). Among these groups, children hold the largest market share, driven by a significantly higher prevalence rate of 18.3%, compared to 7.7% in adults and 11.6% in older adults. This dominant paediatric share is largely due to early-onset cases, increased clinical attention, and higher diagnosis rates during childhood. Moreover, caregivers are more proactive in seeking medical interventions for children, contributing to stronger demand for paediatric-specific dermatological treatments.

While the prevalence of atopic dermatitis declines with age, the adult (18-74) and older adult (75+) segments still represent a substantial portion of the overall patient population. In contrast to the acute flare-ups more commonly observed in children, atopic dermatitis in adults and older adults often presents as a chronic condition, requiring long-term management strategies. This underscores the growing importance of treatments such as biologics and topical therapies tailored for sustained use and the unique needs of aging skin.

By Gender: Market Segmented into Male and Female, Dominated by Females

Adding another layer of complexity to market dynamics is the gender-based segmentation of atopic dermatitis. The market is divided into male and female segments, with females representing the dominant share. According to 2023 data, atopic dermatitis is more prevalent among females globally, with a 2.8% prevalence rate affecting approximately 108.29 million women, compared to 2.4% in males, or 95.76 million individuals. This consistent female predominance may be attributed to hormonal influences, genetic predisposition, and differences in immune system responses, all of which highlight the importance of gender-informed therapeutic strategies.

As diagnostic capabilities advance and awareness of chronic atopic dermatitis continues to grow, the market is expected to see sustained and diversified growth across both gender segments, with increasing emphasis on tailored treatment solutions.

By Drug Type :Non-Biologics Hold the Largest Share, While Biologics Continue to Establish Their Presence

The atopic dermatitis therapeutic market is primarily segmented into two categories based on drug type: non-biologics and biologics. Non-biologics currently dominate the market and include conventional therapies such as topical corticosteroids, calcineurin inhibitors, and Janus kinase (JAK) inhibitors. These treatments are often used as the first line of defence for moderate to severe eczema, valued for their affordability, accessibility, and well-established safety profiles. Within non-biologics, topical treatments tend to be more affordable than oral options. For instance, Opzelura, a topical JAK inhibitor, has a retail price of around $2,755 without insurance, making it more accessible compared to oral JAKs like Jakafi (Ruxolitinib), which has an average annual list price of $17,150. Insurance plans, including Medicare, can help reduce these costs, but out-of-pocket payments remain a key consideration.

Biologics, meanwhile, represent a fast-growing segment of the market. These injectable therapies began receiving approval for atopic dermatitis in 2017 and now are gaining ground for their ability to precisely target immune pathways. Developed using ultra-modern biotechnology to block specific inflammatory signals, biologics offer high clinical effectiveness but at a much steeper cost. Dupilumab (Dupixent), for example, is priced at about $37,000 per year before discounts. Insurance coverage often depends on long-term cost-effectiveness and clinical necessity. Biologics like Dupilumab is approved for patients as young as six months, Tralokinumab (Adbry) for those 12 and older.

While biologics are reshaping the market with their precision and effectiveness, their high cost and limited access restrict broader adoption. As a result, non-biologics continue to lead, supported by lower prices. However, with more biologics entering the market and pricing models are also evolving, increasing biologics share during the forecast period. 

Overall, the atopic dermatitis therapeutic market landscape is undergoing significant transformation, driven by continued research, shifting cost dynamics, and a growing emphasis on personalized and value-based care.

By Drug Class: Corticosteroids Take the Lead, While JAK Inhibitors and Biologics Gain Momentum

The atopic dermatitis therapeutic market is segmented by drug class into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, JAK inhibitors, antihistamines, and biologics. Among these, corticosteroids hold the largest share and serve as the first line therapies, remaining the mainstay of treatment due to their fast symptom relief and broad applicability. Their versatility in both topical and injectable forms allows for tailored treatment across a range of severities and lesion locations. For more severe flares, injectable corticosteroids, triamcinolone are employed. However, the long-term use of high-potency corticosteroids is tempered by safety concerns, including skin thinning and, in rare cases, an increased risk of lymphoma. As a result, clinicians are adopting more cautious and targeted approaches, often pairing corticosteroids with barrier-supporting agents such as dexpanthenol to mitigate adverse effects.

To address these safety concerns, calcineurin inhibitors like pimecrolimus and tacrolimus have emerged as steroid-sparing alternatives, particularly for delicate areas like the face and intertriginous regions. Though not as fast acting as corticosteroids, they offer a valuable long-term option for patients over two years old, especially when steroid use is contraindicated or not tolerated.

While calcineurin inhibitors offer a non-steroidal approach for sensitive skin areas, PDE4 inhibitors such as crisaborole and roflumilast extend this concept further by providing steroid-free management for mild to moderate cases across broader body regions. Their favourable safety profile, especially in paediatric populations, has made them increasingly popular. The 2021 approval of difamilast in Japan for both adults and children underscores growing international recognition of this class’s value in routine care.

However, for patients with moderate to severe or treatment-resistant atopic dermatitis, the limitations of topical agents have opened the door to JAK inhibitors. This newer class includes both topical formulations, such as ruxolitinib cream (Opzelura), and systemic options like upadacitinib (Rinvoq) and abrocitinib (Cibinqo). JAK inhibitors stand out for their rapid onset of action and robust efficacy, often outperforming older therapies in managing inflammation and chronic itching. Their rising uptake reflects a broader shift toward more targeted, fast-acting systemic treatments for difficult-to-manage cases.

Meanwhile, antihistamines, while not curative, play a supportive role by alleviating one of atopic dermatitis most distressing symptoms - itching. Their ability to improve sleep and reduce nighttime scratching makes them a valuable adjunct in comprehensive management strategies, especially during acute flares.

Finally, biologics represent the most dynamic and fast-growing segment of the atopic dermatitis therapeutic market. Leading this class is dupilumab, which has significantly reshaped the therapeutic landscape due to its high efficacy in moderate to severe disease. Its expanding list of indications reflects both clinical confidence and patient demand for durable, systemic solutions. Compared to traditional immunosuppressants, biologics offer a more targeted mechanism with a favourable safety profile, aligning with the broader trend toward personalized medicine.

As the treatment landscape broadens, the market is shifting toward more personalized and sustained approaches, offering patients improved symptom control and quality of life through a growing range of therapeutic options.

By Distribution Channel: General Pharmacies Lead and Grow, While Hospital Pharmacies Play a Key Role

The atopic dermatitis therapeutic market can be segmented by distribution channel into hospital and clinics and pharmacies. Hospital and clinics play a vital role, particularly for inpatients and patients requiring follow-up care. 

Pharmacy segments include both retail and online outlets. Retail pharmacies continue to be the primary driver within this segment, largely due to their accessibility and established presence in communities. Growth in this channel is fuelled by increasing awareness of atopic dermatitis and prevalent use of over the counter (OTC) products.

Simultaneously, the online pharmacy segment is experiencing rapid expansion. This shift is supported by increasing internet penetration, the digitalization of healthcare services, and evolving consumer preferences. As consumers become more digitally engaged and comfortable with online healthcare solutions, this channel is expected to gain further traction in the coming years.

By Route of Administration: Topicals Dominates, Injectables are Growing Quickly 

The atopic dermatitis therapeutic market is segmented by route of administration into topical, parenteral (injectable), and oral therapies, each playing a distinct role in treatment strategies based on disease severity, patient preference, and therapeutic goals. 

Topical treatments currently dominate the market, accounting for approximately 45% of the total share. These include well-established agents such as corticosteroids and calcineurin inhibitors, which continue to be the first-line choice for mild to moderate cases. Their ease of application, long-standing clinical familiarity, and high patient adherence have helped maintain their stronghold. Despite the surge in advanced therapies, topicals remain foundational, particularly in paediatric and primary care settings.

However, a major shift is underway, led by injectables, primarily biologics and systemic steroids which currently hold 35% of the market and are rapidly gaining ground since their usage began in 2018. Dupixent, developed by Regeneron, has played a pivotal role in reshaping the treatment paradigm for moderate to severe atopic dermatitis. In 2024, Dupixent alone generated USD 14.1 billion globally across all indications, reflecting its dominance. More recently, biologics such as Adbry (approved in 2021) and Ebglyss (approved in 2024) are steadily expanding the market, supported by positive clinical outcomes and growing physician confidence. These high-efficacy therapies not only command premium pricing but also exhibit the fastest compound annual growth rate (CAGR) across all segments in the atopic dermatitis therapeutic market.

Whereas, oral therapies complete the landscape, contributing approximately 20% to the market. Typically prescribed when topical treatments are insufficient or unsuitable, oral options provide a critical bridge between first line and advanced therapies. While their share is smaller, their importance remains significant. Drugs like Cibinqo, developed specifically for atopic dermatitis, generated USD 215 million in 2024, whereas Rinvoq, with broader indications, brought in USD 1.83 billion, underscoring its commercial success. Though oral therapies lack the biological precision of injectables, their ease of administration and systemic reach make them attractive for few patient groups and support their steady growth trajectory.

 To Understand More About this Research:  Request A Free Sample 

By Region: Atopic Dermatitis Therapeutics Market, Led by North America, Followed by Europe 

The global atopic dermatitis therapeutic market is segmented into North America, Europe, Asia-Pacific, and the Middle East, with North America currently leading the landscape. This dominance stems from a combination of high disease prevalence, advanced therapeutic adoption, and a well-established healthcare infrastructure. In the United States alone, atopic dermatitis affects approximately 1 in 10 adults, translating to over 16.5 million individuals. Of these, about 6.6 million suffer from moderate to severe forms, highlighting a significant need for advanced treatments.
Crucially, North America’s edge lies in the widespread use and coverage of advanced therapies, including biologics and Janus kinase (JAK) inhibitors. Insurance systems such as employer-sponsored plans, Medicare (for those over 65 or with disabilities), Medicaid, and CHIP play a critical role in ensuring patient access, especially under the Affordable Care Act, which mandates coverage for essential treatments prescribed by specialist.

In comparison, Europe follows closely in terms of market maturity, with 4.4% of adults and up to 18.6% of children and adolescents affected with atopic dermatitis. 
While Europe does not match North America in terms of biologic adoption pace, it boasts a robust healthcare system and strong dermatological expertise, particularly in countries like Germany. The region also faces significant economic impact, with annual societal costs reaching USD 34 billion in the process of treating atopic dermatitis, indicating the scale of unmet needs and market potential. While insurance and access systems vary by country, most European nations offer broad reimbursement for necessary therapies, supporting steady market growth.

Meanwhile, the Asia-Pacific region emerges as the fastest- growing market, driven by rising prevalence, evolving healthcare systems, and increasing consumer health awareness. However, access to advanced therapies remains inconsistent across the region due to regulatory variability and affordability constraints. For example, while countries like Japan and South Korea are rapidly integrating biologics, other markets rely more heavily on traditional treatments like topical corticosteroids. Nonetheless, the region's expanding middle class and increasing healthcare spending position it as a high-growth zone, especially for companies that can tailor strategies to diverse local needs.

The Middle East, though currently smaller in market size, is also gaining traction, propelled by urbanization, rising awareness, and increased government healthcare investment. Countries such as the UAE and Saudi Arabia are investing in dermatology infrastructure and showing interest in biologics and other targeted therapies. Although prevalence is relatively lower compared to other regions, the strategic focus of pharmaceutical firms on partnerships and local collaborations is unlocking long-term potential.

 Recent Developments

March 8, 2025: VTAMA Cream Shows Long-Lasting Relief in Atopic Dermatitis After Treatment Pause

Phase 3 data from the ADORING 3 trial show that 1% VTAMA (tapinarof) cream in adults and children aged 2 and up, maintains a low disease activity in atopic dermatitis even after stopping treatment. Following an average 80-day treatment-free period, 84% of patients had only mild disease (vIGA-AD score of 2), and the mean itch score (PP-NRS) was 2.9, indicating sustained symptom control. These results support VTAMA’s potential for durable remission.

February 2025: Galderma’s Nemluvio (Nemolizumab) Receives Approval for Atopic Dermatitis and Prurigo Nodularis in the UK and Switzerland
Galderma’s Nemluvio (nemolizumab), a first-in-class monoclonal antibody targeting IL-31 receptor alpha, has received approval in the UK and Switzerland for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN). In Phase III trials, Nemluvio significantly improved itch, skin lesions, and sleep quality, offering a novel, targeted treatment for these debilitating conditions.

February 2025: Nektar Therapeutics Receives FDA Fast Track Designation for Rezpegaldesleukin in Atopic Dermatitis

Nektar Therapeutics has received FDA Fast Track designation for rezpegaldesleukin to treat moderate-to-severe atopic dermatitis in patients aged 12 and older, which are inadequately controlled by topical therapies. This investigational biologic targets the interleukin-2 receptor complex to stimulate regulatory T cells and modulate the immune system. Clinical trials have shown significant improvements within 12 weeks, with benefits lasting up to 36 weeks post-treatment. The designation allows for accelerated development and more frequent FDA interactions. Phase 2b REZOLVE-AD study results are expected in mid-2025.

January 2025: Gilead Sciences Partners with LEO Pharma on STAT6 Inflammatory Disease Program

Gilead Sciences has signed a licensing agreement with LEO Pharma to develop and commercialize LEO’s oral STAT6 inhibitor program targeting inflammatory diseases such as atopic dermatitis, asthma, and COPD. Under the terms, LEO will receive up to $1.7 billion, including an upfront payment of $250 million, while Gilead secures global rights to develop, manufacture, and commercialize the oral formulations. LEO will retain rights to topical STAT6 products and earn tiered royalties ranging from high single digits to mid-teens. The deal is expected to reduce Gilead’s 2025 earnings per share by approximately $0.15 to $0.17, reflecting its strategic investment in expanding its immunology pipeline.

Key Competitors

• AbbVie
• Arcutis Biotherapeutics
• Bausch Health
• Eli Lilly
• Galderma
• Leo Pharma
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• Torii Pharmaceuticals
• Other Prominent Players

Market Segmentation Overview

By Age

• Children
• Adults
• Older Adults

By Gender

• Male
• Female

By Drug Type 

• Biologics
• Non-biologics

By Drug Class 

• Corticosteroids
• Calcineurin Inhibitors
  • Pimecrolimus
  • tacrolimus
• PDE4 Inhibitors
  • Crisaborole
  • Roflumilast
  • Difamilast
• JAK inhibitors
  • Oral
• Upadacitinib (Rinvoq)
• Abrocitinib (Cibinqo)
• Baricitinib (Olumiant)
• Topical:  Ruxolitinib cream (Opzelura)
• Antihistamines
  • Cetirizine
  • Loratadine
  • Hydroxyzine
• Biologics
  • Dupilumab
  • Tralokinumab (Adbry)
  • Lebrikizumab
  • Nemolizumab

 By Route of Administration 

• Topical
• Oral
• Injectable

By Distribution Channel 

• Hospital & Clinics
• Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography    

•  North America   
  • The USA
  • Canada
  • Mexico
• Europe   
  • Western Europe   
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific   
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa   
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America    
  • Argentina
  • Brazil
  • Rest of South America